Bayer Shares Climb as Operational Wins Offset Institutional Selling

Bayer shares rose 1.6% as new drug approvals in Asia boosted sentiment, overshadowing a reduction in Goldman Sachs's voting rights stake. The stock is up nearly 80% over the past year.

Despite a notable reduction in holdings by a major US investment bank, Bayer AG's stock demonstrated resilience on Tuesday, closing the day with a solid gain. The shares advanced by 1.60 percent, reaching a price of €39.59 and edging closer to the psychologically significant €40 threshold. Positive developments within the company's pharmaceutical division, particularly in Asian markets, are credited with buoying investor sentiment and overshadowing the institutional divestment.

Operational Momentum from Pharma Approvals

The recent upward movement is supported by concrete regulatory successes. In Japan, Bayer has secured key authorizations for two products: the eye treatment Eylea 8 mg for a third indication, and a novel MRI contrast agent called Gadopiclenol. These milestones are central to the company's strategic efforts to counter revenue declines from older medications losing patent protection. The stock's performance over a longer horizon underscores a significant recovery, boasting an impressive 79.57 percent increase over the past twelve months.

Goldman Sachs Adjusts Its Position

The institutional activity stems from a recent voting rights notification. Goldman Sachs reduced its total share of voting rights and related instruments from 6.34 percent to 4.13 percent. A detailed look reveals an interesting shift: while directly held voting rights saw a marginal increase to 0.25 percent, there was a pronounced reduction in financial instruments, which now stand at 3.88 percent. The market's ability to absorb this decrease without visible weakness points to underlying strength in the share price.

Upcoming Catalysts and Financial Targets

Investor attention is now turning to scheduled events for the second quarter that are expected to provide fresh direction.

• April 24, 2026: The Annual Stockholders' Meeting, where a dividend proposal of €0.11 per share will be presented.
• May 12, 2026: The release of first-quarter financial results.

For the full 2026 fiscal year, Bayer's management has set a target for core earnings per share between €4.30 and €4.80. This forecast will serve as a fundamental benchmark for assessing the upcoming quarterly reports and the stock's future trajectory.